RTS, S is the leading malaria vaccine in development, but has demonstrated only moderate
protective efficacy in clinical trials. RTS, S is a virus-like particle (VLP) that uses the human …

The N-terminal domain of the circumsporozoite protein (CSP) has been largely neglected in
the search for a malaria vaccine in spite of being a target of inhibitory antibodies and …

This study describes the safety and immunogenicity of a liposome-based vaccine injected
into human subjects. Thirty healthy adult male volunteers were immunized with a liposome …

The circumsporozoite protein (CSP) of Plasmodium falciparum is a major surface protein,
which forms a dense coat on the sporozoite's surface. Preclinical research on CSP and …

We have developed FMP014, a vaccine candidate against Plasmodium falciparum malaria,
which is comprised of 60 identical monomer protein chains that form an icosahedral shaped …

A Plasmodium falciparum circumsporozoite protein (PfCSP) recombinant fusion protein,
R32NS1 (81), formulated with monophosphoryl lipid A, cell wall skeleton of mycobacteria …

Twenty malaria-naive volunteers received a recombinant Plasmodium falciparum malaria
vaccine (RTS, S) containing 19 NANP repeats and the carboxy terminus (amino acids 210 …

A major malaria vaccine candidate, the circumsporozoite (CS) protein of Plasmodium, is a
pre-erythrocytic stage antigen that is attached to the surface of the sporozoites through a …

Plasmodium vivax is the major cause of malaria outside of sub-Saharan Africa and causes
morbidity and results in significant economic impact in developing countries. In order to …

ABSTRACT A Plasmodium falciparum circumsporozoite protein (CSP)-based recombinant
fusion vaccine is the first malaria vaccine to reach phase III clinical trials. Resistance to …